Cited by 274Advanced Glycation End Products researchChronic Kidney Disease and DiabetesSkin Diseases and Diabetes

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

The Role of Advanced Glycation End Products in Diabetic Vascular Complications

Open access
Rhee, Sang Youl, Kim, Young Seol·2018·Diabetes & Metabolism Journal

Abstract

In cases of chronic hyperglycemia, advanced glycation end-products (AGEs) are actively produced and accumulated in the circulating blood and various tissues. AGEs also accelerate the expression of receptors for AGEs, and they play an important role in the development of diabetic vascular complications through various mechanisms. Active interventions for glucose and related risk factors may help improve the clinical course of patients by reducing AGEs. This review summarizes recent updates on AGEs that have a significant impact on diabetic vascular complications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4093/dmj.2017.0105

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Suggested mechanism of advanced glycation end-products (AGEs) in diabetic vascular complications. RAGE, receptor for advanced glycation end-product; NF-κB, nuclear factor κB; RAS, renin-angiotensin system; TZD, thiazolidinediones; GLP-1, glucagon like peptide-1; DPP-4, dipeptidylpeptide-4; sRAGE, soluble receptor for advanced glycation end-product; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; NADPH, nicotinamide adenine dinucleotide phosphate; IL, interleukin; TNF-α, tumor necrosis factor α.
Fig. 1 Suggested mechanism of advanced glycation end-products (AGEs) in diabetic vascular complications. RAGE, receptor for advanced glycation end-product; NF-κB, nuclear factor κB; RAS, renin-angiotensin system; TZD, thiazolidinediones; GLP-1, glucagon like peptide-1; DPP-4, dipeptidylpeptide-4; sRAGE, soluble receptor for advanced glycation end-product; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; NADPH, nicotinamide adenine dinucleotide phosphate; IL, interleukin; TNF-α, tumor necrosis factor α.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. Soulis-Liparota, 1991, Diabetes, 40, 1328, 10.2337/diab.40.10.1328 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rhee, S. Y., & Kim, Y. S.
Affiliations
Kyung Hee University (KR)
Corresponding author
Kim, Young Seol
Venue
Diabetes & Metabolism Journal
Published
2018
Volume
42
Issue
3
Pages
188
ISSN
  • 2233-6079 (ISSN-L)
  • 2233-6087
OpenAlex
W2806671364
Cited by
274
References
52
Citations by year
2026: 20 · 2025: 33 · 2024: 20 · 2023: 25 · 2022: 44 · 2021: 58 · 2020: 46 · 2019: 24 · 2018: 3
FWCI
4.26
Type
journal article
Language
en
Open access
Locations
  • Diabetes & Metabolism Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministry of Health and Welfare (HI10C2020)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
Keywords
advanced glycation end products, diabetic vascular complications, chronic hyperglycemia, AGE receptor, AGE formation, glycemic control, diabetes complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review